Drug susceptibility and replicative capacity of multidrug-resistant recombinant human cytomegalovirus harboring mutations in UL56 and UL54 genes

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 11, 2017, Pages

  Piret, Jocelyne ^a   Goyette, Nathalie ^a   Boivin, Guy ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Antiviral agents; Cytomegalovirus; Resistance

Indexed keywords

ANTIVIRUS AGENT; BRINCIDOFOVIR; CIDOFOVIR; FOSCARNET; GANCICLOVIR; LETERMOVIR; DNA DIRECTED DNA POLYMERASE; UL54 PROTEIN, HUMAN HERPESVIRUS 5; UL56 PROTEIN, CYTOMEGALOVIRUS; VIRAL PROTEIN;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; GENE MUTATION; GENETIC RECOMBINATION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IN VITRO STUDY; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; UL54 GENE; UL56 GENE; VIRUS GENE; VIRUS RECOMBINANT; VIRUS REPLICATION; WILD TYPE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DNA REPLICATION; DRUG EFFECT; FIBROBLAST; GENETICS; MUTATION; VIROLOGY;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA REPLICATION; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, MULTIPLE, VIRAL; FIBROBLASTS; HUMANS; MUTATION; VIRAL PROTEINS; VIRAL STRUCTURAL PROTEINS;

EID: 85032513480     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01044-17     Document Type: Article

References (18)

1. Kotton CN. 2013. CMV: prevention, diagnosis and therapy. Am J Transplant 13(Suppl 3):24–40; quiz 40. https://doi.org/10.1111/ajt.12006.
2. Andrei G, de Clercq E, Snoeck R. 2009. Viral DNA polymerase inhibitors, p 481–526. In Cameron CE, Gotte M, Raney K (ed), Viral genome replication. Springer, New York, NY.
3. Lurain NS, Chou S. 2010. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 23:689–712. https://doi.org/10.1128/CMR.00009-10.
4. Drouot E, Piret J, Lebel MH, Boivin G. 2014. Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping. J Clin Microbiol 52:4043–4046. https://doi.org/10.1128/JCM.02205-14.
5. Hostetler KY. 2010. Synthesis and early development of hexadecyl-oxypropylcidofovir: an oral antipoxvirus nucleoside phosphonate. Viruses 2:2213–2225. https://doi.org/10.3390/v2102213.
6. Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. 2011. The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol 85: 10884–10893. https://doi.org/10.1128/JVI.05265-11.
7. Goldner T, Hempel C, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. 2014. Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. Antimicrob Agents Chemother 58:610 – 613. https://doi.org/10.1128/AAC.01794-13.
8. Lischka P, Michel D, Zimmermann H. 2016. Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK (8228). J Infect Dis 213:23–30. https://doi.org/10.1093/infdis/jiv352.
9. Marty FM, Ljungman PT, Chemaly RF et al. 2017. A phase III randomized, double-blind, placebo-controlled trial of letermovir for prevention of cytomegalovirus infection in adult CMV-seropositive recipients of allo-geneic hematopoietic cell transplantation, abstr LBA2. Abstr 2017 BMT Tandem Meetings, Orlando, FL.
10. Fuji S, Einsele H, Kapp M. 2017. Cytomegalovirus disease in hematopoietic stem cell transplant patients: current and future therapeutic options. Curr Opin Infect Dis 30:372–376. https://doi.org/10.1097/ QCO.0000000000000375.
11. Borst EM, Hahn G, Koszinowski UH, Messerle M. 1999. Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J Virol 73:8320 – 8329.
12. Drouot E, Piret J, Boivin G. 2013. Novel method based on “en passant” mutagenesis coupled with a Gaussia luciferase reporter assay for studying the combined effects of human cytomegalovirus mutations. J Clin Microbiol 51:3216–3224. https://doi.org/10.1128/JCM.01275-13.
13. Tischer BK, Smith GA, Osterrieder N. 2010. En passant mutagenesis: a two step markerless red recombination system. Methods Mol Biol 634: 421–430. https://doi.org/10.1007/978-1-60761-652-8_30.
14. Chou S, Lurain NS, Thompson KD, Miner RC, Drew WL. 2003. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis 188:32–39. https://doi.org/10.1086/375743.
15. Chevillotte M, Schubert A, Mertens T, von Einem J. 2009. Fluorescence-based assay for phenotypic characterization of human cytomegalovirus polymerase mutations regarding drug susceptibility and viral replicative fitness. Antimicrob Agents Chemother 53:3752–3761. https://doi.org/10.1128/AAC.00165-09.
16. Goldner T, Zimmermann H, Lischka P. 2015. Phenotypic characterization of two naturally occurring human Cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in vitro resistance to letermovir. Antiviral Res 116:48–50. https://doi.org/10.1016/j.antiviral.2015.01.006.
17. Krosky PM, Underwood MR, Turk SR, Feng KW, Jain RK, Ptak RG, Wester-man AC, Biron KK, Townsend LB, Drach JC. 1998. Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56. J Virol 72:4721–4728.
18. Chou S. 2015. Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance. Antimicrob Agents Chemother 59:6588–6593. https://doi.org/10.1128/AAC.01623-15.